News

The ALS Society of Canada is honoured to welcome five new members to its Board of Directors. Their professional accomplishments, combined with a personal understanding of the impact of ALS from the perspective of a neurologist, caregiver, or people living…

ALS Canada expresses deep gratitude to four departing members of our Board of Directors who have completed their terms this year. Thank you, Dr. Ken Chan, Dr. Leslie Green, Dr. Wendy Johnston, and Craig Storey, for your dedication, leadership, and…

June’s ALS Awareness Month offers a critical opportunity to shine a light on a fatal disease that remains largely underfunded and under-recognized TORONTO – The ALS Society of Canada (ALS Canada) is calling on Canadians to unite in support of people…

Empowering post-secondary students affected by ALS in their educational goals while strengthening care and support of the ALS community For the third year, the ALS Society of Canada (ALS Canada), together with the family and friends of Kevin Daly, is…

Brain imaging is one of the most powerful tools to help us study ALS. By providing a way to look inside people living with ALS, imaging techniques are giving researchers a unique understanding of what is happening in the disease,…

ALS researchers worldwide continue to build upon existing work and make new discoveries in the hopes of a world free of ALS. In the April 2025 Research Update, explore new insights into clinical trial data, new treatment targets, predicting disease…

In a significant moment for the ALS community, Qalsody (tofersen) has been approved in Canada for the treatment of ALS in adults who have a pathogenic variant (also known as a mutation) in the superoxide dismutase 1 (SOD1) gene. This…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada's advocacy efforts as well as relevant developments within the government. Please note that because ALS Canada…